FDA Approves Lamassu's Innovative Cancer Treatment for Clinical Trials

Cleveland, OH, April 11, 2024 – In a significant development for the medical community, Lamassu Biotech has received FDA approval to initiate Phase 1/2a clinical trials for a groundbreaking cancer treatment. The company's novel therapy, SA53-OS, is a genetically targeted treatment designed to combat locally advanced metastatic p53 wild-type tumors by focusing on the MDM2 protein, which is a significant regulator of the p53 gene.

This innovative approach aims to selectively activate the p53 gene, thereby inducing the death of tumor cells and preventing their growth. The potential of this therapy is immense, as the p53 gene is functional in approximately half of all cancers, and could offer a new direction in cancer treatment for those with limited options.

The collaboration with the Cleveland Clinic, led by Dr. Peter Anderson, aims to develop a treatment that could revolutionize the way cancer is managed, particularly for those who do not respond to traditional chemotherapy. The FDA's IND approval follows Lamassu's receipt of a substantial Small Business Innovation Research (SBIR) grant from the National Institutes of Health, which will support the clinical trial.

Dr. Gabi Hanna, CEO of Lamassu, highlighted the significance of this approval, stating that it represents a pivotal move towards targeted therapies that could offer hope and healing to millions suffering from cancers resistant to conventional treatments. The company's commitment to reducing the toxicity of cancer treatments is also a key focus.

Lamassu's mission is to expedite the development and delivery of innovative therapies, bringing them from the lab to patients more rapidly and with improved outcomes. The company's patient-centric research approach is geared towards addressing unmet medical needs with novel strategies, ensuring efficiency and shorter approval times.

With a team of dedicated professionals including physicians, engineers, and scientists, Lamassu is driven by the passion to treat patients with care and compassion. Their experience in developing leading medical treatments underscores their belief that hope and science are equally vital in the pursuit of healing.

The successful development and approval of SA53-OS, which is already patented in 69 countries, could have a profound impact on the global fight against cancer, offering a new avenue for treatment and potentially saving countless lives.